The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,325.00
Bid: 1,324.00
Ask: 1,327.00
Change: -3.00 (-0.23%)
Spread: 3.00 (0.227%)
Open: 1,325.00
High: 1,328.00
Low: 1,297.00
Prev. Close: 1,328.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

SID & Chair of Remuneration Committee

16 Feb 2023 15:00

RNS Number : 1944Q
Indivior PLC
16 February 2023
 

February 16, 2023

 

Senior Independent Director & Chair of Remuneration Committee

 

 

Indivior PLC (the "Company") today announces that Juliet Thompson has been appointed as Senior Independent Director with effect from October 1, 2023. Juliet has been a Non-Executive Director since March 2021 and is the Chair of the Audit Committee and a member of the Nomination & Governance Committee.

 

The Company further announces that Jo Le Couilliard has been appointed as Chair of the Remuneration Committee also with effect from October 1, 2023. Jo has been a Non-Executive Director since March 2021 and is a member of the Audit and Remuneration Committees.

 

This announcement follows the Company's previous announcement on October 13, 2022 that Daniel J. Phelan, current Senior Independent Director and Chair of the Remuneration Committee, will stand down from the Board on September 30, 2022 having served as a Director for nine years.

 

This announcement is made pursuant to Listing Rule 9.6.11.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 900 individuals globally and its portfolio of products is available in 39 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

For Further Information

 

Jason Thompson

VP, Investor Relations

Indivior PLC

+1 804 402 7123

jason.thompson@indivior.com

Tim Owens

Director, Investor Relations Indivior PLC

+1 804 263 3978

timothy.owens@indivior.com

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAEALAKFAADEFA
Date   Source Headline
27th Jun 202311:00 amRNSNotice of Results
21st Jun 20234:00 pmRNSHolding(s) in Company
16th Jun 20234:00 pmRNSHolding(s) in Company
15th Jun 20234:00 pmRNSHolding(s) in Company
14th Jun 20234:00 pmRNSHolding(s) in Company
14th Jun 20234:00 pmRNSHolding(s) in Company
13th Jun 20234:00 pmRNSHolding(s) in Company
12th Jun 20237:00 amRNSIndivior to Commence Trading on Nasdaq
7th Jun 20233:45 pmRNSHolding(s) in Company
2nd Jun 20235:17 pmRNSIndivior settles antitrust MDL with states and DC
1st Jun 20239:11 amRNSTotal Voting Rights
26th May 20234:20 pmRNSHolding(s) in Company
25th May 20232:30 pmRNSIndivior to Participate in Upcoming Conferences
24th May 20233:05 pmRNSHolding(s) in Company
23rd May 20236:05 pmRNSIndivior Files Form 20-F for US Listing
23rd May 20232:42 pmRNSHolding(s) in Company
23rd May 20238:30 amRNSHolding(s) in Company
23rd May 20237:00 amRNSUS FDA Approves OPVEE
12th May 20232:56 pmRNSHolding(s) in Company
10th May 20233:30 pmRNSDirector/PDMR Shareholding
10th May 202312:00 pmRNSBlock listing Interim Review
10th May 20238:51 amRNSHolding(s) in Company
4th May 20232:48 pmRNSResult of AGM
27th Apr 202312:00 pmRNS1st Quarter Results
25th Apr 20232:30 pmRNSIndivior to Participate in Conference
25th Apr 20239:26 amRNSHolding(s) in Company
20th Apr 20238:43 amRNSHolding(s) in Company
18th Apr 20238:09 amRNSHolding(s) in Company
17th Apr 20234:25 pmRNSHolding(s) in Company
11th Apr 20232:00 pmRNSNotice of Q1 Results
6th Apr 202312:24 pmRNSHolding(s) in Company
3rd Apr 20239:35 amRNSTotal Voting Rights
30th Mar 20232:37 pmRNSHolding(s) in Company
28th Mar 20233:21 pmRNSHolding(s) in Company
27th Mar 202311:42 amRNSAnnual Financial Report
24th Mar 20232:30 pmRNSDirector/PDMR Shareholding
23rd Mar 202310:02 amRNSBlock Listing of Shares
22nd Mar 20233:00 pmRNSDirector/PDMR Shareholding
16th Mar 20232:30 pmRNSDirector/PDMR Shareholding
15th Mar 20232:30 pmRNSDirector/PDMR Shareholding
13th Mar 20234:04 pmRNSDirector/PDMR Shareholding
13th Mar 20232:36 pmRNSHolding(s) in Company
8th Mar 20239:42 amRNSDirector/PDMR Shareholding
6th Mar 20234:00 pmRNSDirector/PDMR Shareholding
6th Mar 202310:21 amRNSHolding(s) in Company
2nd Mar 20231:56 pmRNSIndivior Completes Opiant Transaction
2nd Mar 20238:43 amRNSCompletion of Share Repurchase Program
1st Mar 20234:35 pmRNSDirector/PDMR Shareholding
1st Mar 202310:09 amRNSTotal Voting Rights
1st Mar 20237:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.